T. Rowe Price Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.23M | Buy |
|
|||||
|
2025
Q2 | $1.31M | Buy |
|
|||||
|
2025
Q1 | $1.01M | Buy |
|
|||||
|
2024
Q4 | $954K | Sell |
|
|||||
|
2024
Q3 | $17.1M | Buy |
|
|||||
|
2024
Q2 | $12M | Buy |
|
|||||
|
2024
Q1 | $665K | Buy |
|
|||||
|
2023
Q4 | $681K | Buy |
|
|||||
|
2023
Q3 | $739K | Buy |
|
|||||
|
2023
Q2 | $675K | Buy |
|
|||||
|
2023
Q1 | $729K | Buy |
|
|||||
|
2022
Q4 | $962K | Buy |
|
|||||
|
2022
Q3 | $1.03M | Buy |
|
|||||
|
2022
Q2 | $806K | Sell |
|
|||||
|
2022
Q1 | $1.32M | Sell |
|
|||||
|
2021
Q4 | $1.22M | Sell |
|
|||||
|
2021
Q3 | $1.35M | Buy |
|
|||||
|
2021
Q2 | $1.46M | Sell |
|
|||||
|
2021
Q1 | $976K | Buy |
|
|||||
|
2020
Q4 | $651K | Buy |
|
|||||
|
2020
Q3 | $121K | Buy |
|
|||||
|
2020
Q2 | $53K | Buy |
|
|||||
|
2020
Q1 | $21K | Sell |
|
|||||
|
2019
Q4 | $45K | Buy |
|
|||||
|
2017
Q4 | – | Sell |
|
|||||
|
2017
Q3 | $146K | Buy |
|
|||||
|
2016
Q1 | – | Sell |
|
|||||
|
2015
Q4 | $7.74M | Sell |
|
|||||
|
2015
Q3 | $12.6M | Buy |
|
|||||
|
2014
Q4 | – | Sell |
|
|||||
|
2014
Q3 | $167K | Buy |
|
|||||
|
2014
Q2 | – | Sell |
|
|||||
|
2014
Q1 | $16.7M | Buy |
|